OnCore Biopharma Licenses Second-Generation Cyclophilin Inhibitors From NeuroVive for the Treatment of Chronic HBV Infection
09. September 2014 03:00 ET
|
OnCore Biopharma, Inc.
OnCore Secures Exclusive Worldwide Rights to NVP018
NVP018 Will Complement OnCore's Existing Pipeline Directed at Achieving All-Oral Cure for HBV
DOYLESTOWN, Pa., Sept. 9, 2014 (GLOBE NEWSWIRE)...
OnCore Biopharma Closes Series R Financing
05. September 2014 07:00 ET
|
OnCore Biopharma, Inc.
Funds to Expand OnCore's Portfolio of Oral Therapeutics for the Treatment of Chronic HBV
OnCore to Advance HBV Compounds Into Phase 1 Clinical Development During 2015
Former Pharmasset Team...